The partnership will see Nanowear’s SimpleSense nanotechnology-enabled wearable, mobile and software diagnostics platform take data from the Dexcom G7 CGM, combining continuous glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics. This can deliver real-world and real-time cardometabolic diagnostic assessments, according to a news release.
For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data. This delivers first-in-the-world, home-based, self-administered, continuous cardiometabolic assessments.
Nanowear and Dexcom’s integration could help measure and understand risk factors for cardiovascular disease. The companies could move clinicians closer to early diagnosis and individualized preventative care.
“Our Nanowear-Dexcom integration and data partnership will be a unique offering in clinical research,” says Venk Varadan, CEO and fo-founder of Nanowear. “With the addition of CGM, our platform of 85+ cardiopulmonary and hemodynamic biomarkers now becomes the first-and-only self-administered cardiometabolic assessment of 9 combinatorial, time synchronous diagnostic tools and structured data channels through a single app, iOS or Android.
“There is high demand in the CRO and DTC research communities for a true home-based cardiometabolic assessment that can be self-administered – sponsors want to uncover novel correlative diagnostics utilizing our proven AI approaches in cardiometabolic health.”
